INTRODUCTION

Hematopoietic stem cell transplant [HSCT] recipients have a high risk of acquiring invasive fungal infection [IFI] by virtue of prolonged myelosuppression.\(^1\) Mucormycosis is a devastating invasive fungal disease whose incidence has increased during the past decade.\(^2,3\) This mold belongs to the order Mucorales, which includes Mucor, Rhizopus, and Absidia.\(^4-6\)

Mucormycosis now represents a major threat in transplant recipients, accounting for 2% and 8% of invasive fungal infections in recent cohorts of solid-organ and allogeneic stem-cell transplant recipients, respectively,\(^2\) with an overall 1-year survival of less than 20%.\(^2\) The most common form is rhino cerebral followed by pulmonary, cutaneous, gastrointestinal and disseminated. In the disseminated form, the most commonly involved organ is the lung followed by brain, kidney, heart and spleen.\(^3,4,5,7,8\) Isolated splenic involvement in the absence of systemic infection is extremely rare.\(^8\) Hepatic involvement of mucormycosis is also a rare event and is usually thought to arise from gastrointestinal disease, although dissemination uncommonly occurs from other sources.\(^9,10\)

Mucormycosis most often occurs late [>3 months after transplantation], although cases occurring early have been observed. The possible portal of infection seems to be haematogenous or contiguous spread.\(^2\) High index of clinical suspicion and characteristic CT findings lead to early diagnosis.\(^8\)
Histological examination of biopsied tissue is the preferred method of diagnosis. Invasion seen on histopathology is needed for confirmation.5

The mainstay of treatment is antifungal therapy with an Amphotericin B, surgery, and correction of the underlying medical condition if possible.5 The highest mortality is seen with disseminated disease and the lowest is seen in infections confined to skin and subcutaneous tissue.8

**CASE REPORT**

Here we discuss the outcome of a young patient with hepatosplenic Mucormycosis, after autologous stem cell transplant. A 42 year old male presented with a diagnosis of stage IVBE, ALK negative anaplastic large cell lymphoma [ALCL]. He was treated with eight cycles of chemotherapy consisting of CHOP/IT and consolidative radiotherapy to initial site of bulky disease followed by complete metabolic resolution of disease on end of treatment PET scan. He was planned for high dose therapy [HDT] and autologous stem cell transplant [ASCT]. After two sessions of apharesis, 2.4 million cells / kg body weight were collected. High dose therapy [BEAM] was given followed by reinfusion of stem cells. His post-transplant period was complicated by neutropenic colitis that was managed appropriately. He was discharged on 19th post-transplant day with full engraftment. Restaging scans post HDT /ASCT was performed on day 100, which showed interval development of multiple focal hepatic and splenic hypo densities [Fig.1: A & B] for which a CT guided splenic biopsy was taken.

Histopathology showed necrotic debris with numerous non septate ribbon like fungal hyphae suggestive of mucormycosis [Fig.1: C & D].
Mucormycosis is a rare fungal infection, doing well and remains in remission. Currently he is completely asymptomatic during this whole follow-up period. His subsequent USG scan showed interval decrease in size of splenic hypo-densities that were finally resolved on USG scan [11 months from diagnosis of mucormycosis]. Currently he is doing well and remains in remission.

**DISCUSSION**

Mucormycosis is a rare fungal infection, particularly seen in immunocompromised patients. This mold belongs to Mucorales family. Invasive aspergillosis is the commonest fungal infection in stem cell transplant setting followed by candidiasis and mold infections. In the liver, common fungal infection is candidiasis. Mold infections are associated with worse outcome compared other fungal infections. Post ASCT, invasive fungal infection [IFI] usually occurs in pre-engraftment period however can happen after count recovery as well. Mucormycosis is a late complication in transplant patients, often seen beyond 90 days of transplant and associated with significant morbidity and mortality. Fungal infections produce nodular infiltrates or masses in the organs. Amphotericin B and surgery, in selected cases, are major treatment options. Liposomal Amphotericin and lipid formulations are less toxic than conventional amphotericin and therefore, are preferred choices. Duration of the treatment varies according to disappearance of symptoms and signs. In this particular case, onset of mucormycosis was relatively in early period in timescale. Hepatosplenic mucormycosis is uncommon in transplant patients.

Because of multiple lesions, surgery was not an option in this particular case. Fortunately, after prolonged treatment with amphotericin, all lesions disappeared. The patient remains in good health, being three years post initial presentation with the diagnosis of ALCL.

In conclusion, although mucormycosis is a serious and could be fatal in significant number of patients, but early detection and appropriate treatment may lead to excellent outcome. Although, liposomal and other lipid formulations of amphotericin are better choices, but due to cost, in many developing countries they may not be readily available. In this situation, conventional amphotericin can be started as soon as a patient is diagnosed with mucormycosis.

**Grant Support & Financial Disclosures:** None.

**REFERENCES**

1. Neofytos D, Horn D, Anaissie E, Steincbach W, Olyaei A, Fishman J, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48(3):265-273. doi:10.1086/595846

2. Lanterner F, Sun H-Y, Ribaud P, Singh N, Kontoyiannis DP, Lortholary O. Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis. 2012;54(11):1-8. doi:10.1093/cid/cis195

3. Pagano L, Offidani M, fianchi L, Nosari A, Candoni A, Picardi M, et al. Mucormycosis in hematologic patients. Haematologica. 2004;89(2):207-214.

4. Nosari A, Oreste P, Montillo M, Carrafiello G, Drasci M, Muti G, et al. Mucormycosis in hematologic malignancies: an emerging fungal infection. Haematologica. 2005;85(10):1068-1071.

5. Prabhu R, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect. 2004;10(s1):31-47. doi:10.1111/j.1470-9465.2004.00843.x

6. Hamdi A, Mulanovich VE, Matin SF, Landon G, Sircar K, Tu SM, et al. Isolated renal mucormycosis in a transplant recipient. J Clin Oncol. 2014;33(10):e29-e31. doi:10.1200/JCO.2013.49.1969

7. Song Y, Qiao J, Giovanni G, Liu G, Yang H, Wu J, et al. Mucormycosis in renal transplant recipients: review of 174 reported cases. BMC Infect Dis. 2017;17(1):283. doi:10.1186/s12879-017-2381-4

8. Gupta V, Singh SK, Kakkar N, Jain S, Kalra N, Sokia UN. Splenic and renal mucormycosis in a healthy host: successful management by aggressive treatment. Trop Gastroenterol. 2010;31(1):57-58.

9. Su H, Thompson GR, Cohen SH. Hepatic mucormycosis with abscess formation. Diagn Microbiol Infect Dis. 2012;73(2):192-194. doi:10.1016/j.diagmicrobio.2012.02.021

10. Abboud C, Bergamasco M, Baia C, Lallié MP, Zan AS, Zamarano MM, et al. Case report of hepatic mucormycosis after liver transplantation: successful treatment with liposomal amphotericin B followed by posaconazole sequential therapy. Transplant Proc. 2012;44(8):2501-2502. doi:10.1016/j.transproceed.2012.07.042

**Authors’ Contribution:**

**SY & AH:** Conceived, designed and writing / editing of manuscript. **OW:** Provision of Pathology images. **JM:** Provision of Radiology images. **AH & FS:** Review, editing and final approval of manuscript.